Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Maryland Healthcare Reporter.
Press releases published on June 19, 2025
Symbiotic.blue Launches to Combine Oxford and Cambridge Scientific Brain Power with Bioentrepreneurial Leadership to Reinvent AI Drug Discovery
GlobeNewswire
·
June 19, 2025
LONDON, June 19, 2025 (GLOBE NEWSWIRE) -- Symbiotic.blue, the UK’s newest Techbio company has launched to innovate a next-generation artificial intelligence-driven drug discovery (AIDD) platform by combining the power of generative AI with brain-inspired …
Mega Sardines Named World’s First Seafood “Superfood” by MWA
GlobeNewswire
·
June 19, 2025
MANILA, Philippines, June 19, 2025 (GLOBE NEWSWIRE) -- Mega Sardines, a flagship brand of Mega Prime Foods Inc., has officially been recognized by the U.S.-based Medical Wellness Association (MWA) as the world’s first seafood Superfood, marking a historic …
CancerVax Nanoparticle Successfully Targets Cancer Cells While Sparing Non-cancerous Cells
GlobeNewswire
·
June 19, 2025
Lehi, June 19, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah – June 19, 2025 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform designed to use the body’s immune system to treat cancer, today announced that its ligand conjugated …
HLTH Inc. Unveils HLTH.rad — A Bold New Global Gathering for Imaging Innovators Co-Located with HLTH Europe 2026 in Amsterdam
GlobeNewswire
·
June 19, 2025
AMSTERDAM, Netherlands, June 19, 2025 (GLOBE NEWSWIRE) -- HLTH Inc., the leading global platform for health innovation, is proud to announce the launch of HLTH.rad, a groundbreaking new event that will redefine the future of medical imaging, diagnostics, …
Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
June 19, 2025
Strong cash position of CHF2.8 million at end of Q1 2025 GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to our phase 2 mGlu2 PAM asset, ADX71149 Indivior advanced GABAB PAM Substance use …